menu

Advancing the Science of Anemia Due to CKD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Advancing the Science of Anemia Due to CKD

Details
Recommended

Overview

ReachMD Healthcare Image
RestartResume

    Explore the burden, pathogenesis, therapeutic landscape, and scientific advancements of anemia due to chronic kidney disease.

    • Brought to you by

    • Overview

      Anemia due to chronic kidney disease (CKD) is a condition that affects close to 5 million people in the United States1 and is associated with poor clinical outcomes that place burdens on patients and healthcare systems.2 Given its prevalence and clinical impact, it’s important to understand all aspects of this common condition. Learn more about the burden, pathogenesis, therapeutic landscape, and recent scientific advancements for anemia due to CKD in this video.

      References:

      1. Stauffer ME, Fan T. Prevalence of anemia in chronic kidney disease in the United States. PLoS One. 2014;9:e84943.
      2. Pisoni RL, Bragg-Gresham JL, Young EW, et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004;44:94-111.

      © 2024 Akebia Therapeutics, Inc. All rights reserved.
      MED-DS-US-0123 03/24

    Schedule30 May 2024